Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

• Recursion Pharmaceuticals’ stock rises 8% in pre-market to $5.08 after positive trial results. • The Phase 1B/2 TUPELO trial indicates significant reductions in polyp burden for REC-4881, enhancing ...

📚 Master data structures in Java with detailed analyses, practical examples, and clear trade-offs to enhance your programming skills.

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.

Recursion Pharmaceuticals merged with Exscientia, another AI-driven drug discovery company, positioning itself as a potential biotech innovator The company has partnerships with major pharmaceutical ...

Indriya, Aditya Birla Jewellery, unveils flagship store in Chandigarh, marking entry into Punjab: Indriya, Aditya Birla Jewellery, unveils its first store in Chandigarh, marking its debut in the state ...

Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...

Oct 15 (Reuters) - Aditya Birla Fashion and Retail (ADIA.NS), opens new tab said on Wednesday that French luxury retailer Galeries Lafayette will open its first Indian flagship store in Mumbai city ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...